{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:18:20Z","timestamp":1778199500109,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study evaluated the effectiveness of treatment with an indapamide\/amlodipine single-pill combination (SPC) in outpatients with uncontrolled isolated systolic hypertension (ISH) aged over 55\u00a0years in real-life clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a post-hoc analysis of the subgroup of patients with ISH from ARBALET, a 3-month, multicenter, observational, open-label study conducted in Russia among patients with grade I or II hypertension who were either uncontrolled on previous antihypertensive treatment or treatment-na\u00efve. The effectiveness of indapamide\/amlodipine SPC was assessed by the change in office systolic blood pressure (SBP) and the rate of target SBP (&lt;\u2009140\u00a0mmHg) achievement at 2\u00a0weeks, 1\u00a0month and 3\u00a0months, in four age groups: 55\u201359\u00a0years, 60\u201369\u00a0years, 70\u201379\u00a0years, and 80\u00a0years or older.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ARBALET study recruited 2217 patients, of whom 626 had ISH and were included in this post-hoc analysis (mean age 66.1\u2009\u00b1\u20097.8\u00a0years; 165 men [26.4%] and 461 women [73.6%]). Target SBP\u2009&lt;\u2009140\u00a0mmHg was achieved in 43%, 75% and 93% of patients at 2\u00a0weeks, 1 and 3\u00a0months, respectively. SBP decreased from baseline by 18.8\u2009\u00b1\u200910.5\u00a0mmHg, 27.2\u2009\u00b1\u200910.6\u00a0mmHg and 31.8\u2009\u00b1\u20099.9\u00a0mmHg at 2\u00a0weeks, 1\u00a0month and 3\u00a0months, respectively. In the groups of patients aged 55\u201359, 60\u201369, 70\u201379, and\u2009\u2265\u200980\u00a0years, SBP reductions at 3\u00a0months compared with baseline were \u2212\u200930.3\u2009\u00b1\u20099.4, \u2212\u200932.4\u2009\u00b1\u20099.7, \u2212\u200932.5\u2009\u00b1\u200910.7, and \u2212\u200928.9\u2009\u00b1\u20099.6\u00a0mmHg, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This post-hoc analysis of the observational ARBALET study showed that indapamide\/amlodipine SPC was associated with significant reductions in BP and high rates of target BP achievement in a broad age range of patients with ISH treated in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration number<\/jats:title>\n                    <jats:p>ISRCTN40812831.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-022-02514-y","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:38:28Z","timestamp":1646383108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness of indapamide\/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5873-1768","authenticated-orcid":false,"given":"Zh. D.","family":"Kobalava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7001-5855","authenticated-orcid":false,"given":"Eteri L.","family":"Kolesnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-9236","authenticated-orcid":false,"given":"E. K.","family":"Shavarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5456-8545","authenticated-orcid":false,"given":"L. A.","family":"Goreva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-2393","authenticated-orcid":false,"given":"L. V.","family":"Karapetyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"33","key":"2514_CR1","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"2","key":"2514_CR2","first-page":"47","volume":"74","author":"ZD Kobalava","year":"2002","unstructured":"Kobalava ZD, Kotovskaya YV, Aseeva OA, et al. Clinical and demographic characteristics of different variants of hypertension in elderly patients (according to the results of the Russian scientific and practical program ARGUS). Terapevticheskiy Arkhiv. 2002;74(2):47\u201351 (in Russian).","journal-title":"Terapevticheskiy Arkhiv"},{"issue":"1","key":"2514_CR3","first-page":"6","volume":"3","author":"AG Vishnevsky","year":"2016","unstructured":"Vishnevsky AG, Andreev EM, Timonin SA. Mortality from circulatory system diseases and life expectancy in Russia. Demograficheskoye Obozreniye. 2016;3(1):6\u201334 (in Russian).","journal-title":"Demograficheskoye Obozreniye"},{"issue":"5","key":"2514_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.18705\/1607-419X-2018-24-5-586-595","volume":"24","author":"JD Kobalava","year":"2018","unstructured":"Kobalava JD, Shavarova EK, Khomova IA, et al. Fixed-dose combination of amlodipine and indapamide-retard in the treatment of uncontrolled hypertension in people over 55 years of age. Arterial\u2019naya Gipertenziya. 2018;24(5):586\u201394 (in Russian).","journal-title":"Arterial'naya Gipertenziya"},{"issue":"3","key":"2514_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jash.2015.01.002","volume":"9","author":"X Liu","year":"2015","unstructured":"Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197\u2013205.","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"2514_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/01.CIR.95.5.1132","volume":"95","author":"CJ O'Donnell","year":"1997","unstructured":"O\u2019Donnell CJ, Ridker PM, Glynn RJ, et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation. 1997;95(5):1132\u20137.","journal-title":"Circulation"},{"issue":"20","key":"2514_CR7","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2010.650","volume":"303","author":"BM Egan","year":"2010","unstructured":"Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008. JAMA. 2010;303(20):2043\u201350.","journal-title":"JAMA"},{"key":"2514_CR8","doi-asserted-by":"crossref","unstructured":"Kobalava ZD, Shavarova EK, Burtsev YP. Evaluation of the effectiveness of a single pill combination with amlodipine and indapamide in patients older than 55 years old in real-world practice in Russia (ARBALET study) Poster presented at 29th ESH Congress in Milan, Italy, 21\u201324 June 2019.","DOI":"10.1097\/01.hjh.0000571372.74309.88"},{"key":"2514_CR9","first-page":"64","volume":"12","author":"ZD Kobalava","year":"2018","unstructured":"Kobalava ZD, Tolkacheva VV, Bagmanova NC, Khasanova ER. Efficacy and tolerability of Arifam in patients with hypertension aged over 55 years: main results of the ARBALET observational program. Rossiyskiy Kardiologicheskiy Zhurnal. 2018;12:64\u201374 (in Russian).","journal-title":"Rossiyskiy Kardiologicheskiy Zhurnal"},{"issue":"6","key":"2514_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"3","key":"2514_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/HYPERTENSIONAHA.108.119792","volume":"53","author":"OJ Ekundayo","year":"2009","unstructured":"Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458\u201365.","journal-title":"Hypertension"},{"issue":"6","key":"2514_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.113.004876","volume":"130","author":"Y Li","year":"2014","unstructured":"Li Y, Wei FF, Thijs L, et al. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466\u201374.","journal-title":"Circulation"},{"key":"2514_CR13","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331.","journal-title":"Lancet"},{"issue":"23","key":"2514_CR14","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"2514_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1742-1241.2012.02943.x","volume":"66","author":"F Lu","year":"2012","unstructured":"Lu F, Zhao Y, Liu Z, et al. A 48-week study of amlodipine plus amiloride \/ hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension. Int J Clin Pract. 2012;66(8):792\u20139.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"2514_CR16","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, et al. Combination therapy of hypertension to prevent cardiovascular events trial group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649\u201359.","journal-title":"J Hypertens"},{"issue":"18","key":"2514_CR17","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","volume":"358","author":"NS Beckett","year":"2008","unstructured":"Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887\u201398.","journal-title":"N Engl J Med"},{"issue":"9","key":"2514_CR18","first-page":"710","volume":"108","author":"PATS Collaborating Group","year":"1995","unstructured":"PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995;108(9):710\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"9287","key":"2514_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published correction appears in Lancet 2001 Nov 3;358(9292):1556] [published correction appears in Lancet 2002 Jun 15;359(9323):2120]. Lancet. 2001;358(9287):1033\u201341.","journal-title":"Lancet"},{"key":"2514_CR20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA"},{"key":"2514_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895\u2013906.","journal-title":"Lancet"},{"issue":"18","key":"2514_CR22","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217\u201325.","journal-title":"JAMA"},{"key":"2514_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"B Pitt","year":"2000","unstructured":"Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503\u201310.","journal-title":"Circulation"},{"issue":"9080","key":"2514_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757\u201364.","journal-title":"Lancet"},{"issue":"9192","key":"2514_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751\u20136.","journal-title":"Lancet"},{"issue":"12","key":"2514_CR26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","volume":"16","author":"L Liu","year":"1998","unstructured":"Liu L, Wang J, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16(12):1823\u20139.","journal-title":"J Hypertens"},{"key":"2514_CR27","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","volume":"380","author":"D Ojji","year":"2019","unstructured":"Ojji D, Mayosi B, Francis V, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019;380:2429\u201339.","journal-title":"N Engl J Med"},{"issue":"7653","key":"2514_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","volume":"336","author":"F Turnbull","year":"2008","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121\u20133.","journal-title":"BMJ"},{"key":"2514_CR29","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.","journal-title":"BMJ"},{"issue":"12","key":"2514_CR30","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1185\/030079907X242674","volume":"23","author":"J Akram","year":"2007","unstructured":"Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin. 2007;23(12):2929\u201336.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2514_CR31","doi-asserted-by":"publisher","first-page":"e92955","DOI":"10.1371\/journal.pone.0092955","volume":"9","author":"U Jadhav","year":"2014","unstructured":"Jadhav U, Hiremath J, Namjoshi DJ, et al. Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. PLoS ONE. 2014;9(4):e92955.","journal-title":"PLoS ONE"},{"issue":"24","key":"2514_CR32","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255\u201364.","journal-title":"JAMA"},{"issue":"2","key":"2514_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00004872-200102000-00023","volume":"19","author":"JP Emeriau","year":"2001","unstructured":"Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001;19(2):343\u201350.","journal-title":"J Hypertens"},{"key":"2514_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","volume":"304","author":"MRC Working Party","year":"1992","unstructured":"MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405\u201312.","journal-title":"BMJ"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02514-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:39:53Z","timestamp":1646383193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2514"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02514-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-125731\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All diagnostic procedures were performed based on written informed patient consent. The study was conducted in accordance with the principles of Good Clinical Practice (GCP) and the Declaration of Helsinki. The study protocol was approved by the Ethical Committee for Medical Studies of the People\u2019s Friendship University of Russia (RUDN).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Prof Kobalava has received fees from Servier as a speaker and an investigator. Other authors declare the absence of a potential conflict to disclose in relation to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}